Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Patents and Intangibles (Detail)

v3.21.1
Acquisition of Patents and Intangibles (Detail)
$ / shares in Units, $ in Thousands, shares in Millions
 3 Months Ended
Nov. 16, 2018
USD ($)
item
$ / shares
Nov. 06, 2018
shares
Oct. 16, 2012
USD ($)
Feb. 28, 2021
USD ($)
Nov. 30, 2020
$ / shares
May 31, 2020
USD ($)
Feb. 29, 2020
USD ($)
$ / shares
Nov. 30, 2019
$ / shares
Aug. 31, 2019
$ / shares
Acquired Finite-Lived Intangible Assets [Line Items]                  
Intangible assets, cost       $ 6,446   $ 18,646      
Stock price, in dollars per share | $ / shares         $ 1.50   $ 0.50 $ 0.50 $ 0.50
Patents                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Asset purchase, cash paid     $ 3,500            
Intangible assets, cost       $ 3,500   3,500 $ 3,500    
Estimated useful life of acquired asset       10 years          
Intangible Assets Obtained From ProstaGene L L C [Member]                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Intangible assets, cost       $ 2,926   $ 15,126      
Acquisition of ProstaGene LLC, value $ 11,558                
Shares issued in acquisition | shares   20.3              
Stock price, in dollars per share | $ / shares $ 0.57                
Shares restricted from transfer | shares   8.3              
Common stock shares restriction period 3 years                
Stock repurchase price, per share | $ / shares $ 0.001                
Restricted shares, number of installments | item 3                
Intangible Assets Obtained From ProstaGene L L C [Member] | Over-Allotment Option [Member]                  
Acquired Finite-Lived Intangible Assets [Line Items]                  
Shares issued in acquisition | shares   1.6